Interferon-associated refractory status epilepticus by MILLER, V. S, ZWIENER, R. J, FIELMAN, B. A

Get full text

Integrated telehealth intervention to reduce chronic pain and unhealthy drinking among people living with HIV: protocol for a randomized controlled trial by Palfai, Tibor P, Bernier, Lauren B, Kratzer, Maya Pl, Magane, Kara M, Fielman, Sarah, Otis, John D, Heeren, Timothy C, Winter, Michael R, Stein, Michael D

Get full text

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting by Singh, Simron, Hope, Thomas A, Bergsland, Emily B, Bodei, Lisa, Bushnell, David L, Chan, Jennifer A, Chasen, Beth R, Chauhan, Aman, Das, Satya, Dasari, Arvind, Del Rivero, Jaydira, El-Haddad, Ghassan, Goodman, Karyn A, Halperin, Daniel M, Lewis, Mark A, Lindwasser, O Wolf, Myrehaug, Sten, Raj, Nitya P, Reidy-Lagunes, Diane L, Soares, Heloisa P, Strosberg, Jonathan R, Kohn, Elise C, Kunz, Pamela L

Get full text

Amphitrite ornata, a marine worm, contains two dehaloperoxidase genes by Han, K, Woodin, S A, Lincoln, D E, Fielman, K T, Ely, B

Get full text

623 Safety and pharmacokinetics of NM107 following intravenous infusion of escalating doses in healthy volunteers: Determination of absolute oral bioavailability of valopicitabine... by Zhou, X.J, Knox, S., Fielman, B., Chao, G., Brown, N.

Get full text

624 Absence of effect of pegylated interferon alpha-2b on the pharmacokinetics of valopicitabine (NM283) in patients with chronic hepatitis C by Zhou, X.J., Fielman, B., Chao, G., Knox, S., Brown, N.

Get full text

522 Absence of pharmacokinetic drug-drug interaction between telbivudine and peginterferon alpha-2a or cyclosporine in healthy subjects by Zhou, X.J, Fielman, B., Dubuc-Patrick, G., Chao, G., Brown, N.

Get full text

110 Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the globe study by Thongsawat, S., Lai, C.L., Gane, E., Chao, G., Fielman, B., Brown, N.

Get full text

493 Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year by Gane, E., Lai, C.L., Liaw, Y.E., Thongsawat, S., Wang, Y., Cheng, Y., Heathcote, J., Rasenacks, J., Bzowej, N., Naoumov, N., Chao, G., Fielman, B., Brown, N.

Get full text

51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients by Zeuzem, S., Lai, C.L., Gane, E., Liaw, Y.F., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, J., Rasenack, J., Bzowej, N., Naoumov, N., Chao, G., Fielman, B., Brown, N.

Get full text

96 First clinical results for a novel antiviral treatment for hepatitis C: A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283 by Godofsky, E., Afdhal, N., Rustgi, V., Shick, L., Duncan, L., Zhou, X.J., Chao, G., Fang, C., Fielman, B., Myers, M., Brown, N.A.

Get full text